FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2025 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2025”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of February 2025 we identified the following current VC trends in the United States:

• Total Healthcare & Life Sciences funding reached EUR 6,893m (+14% vs. 2024)
• After a strong start in January with a 64% year-over-year increase, healthcare and life sciences funding in the U.S. has significantly slowed in February
• Biotech/Pharma received 51% of the total investment volume (EUR 3,543m) with immunology being the leading indication (26%)
• In February Eikon Therapeutics secured the highest transaction volume with EUR 337m, followed by Abridge with EUR 240m and Abcuro with EUR 193m
• Accelmed (United States) is the most active investor (by deal volume in 2025), followed by Y Combinator (United States) and F-Prime Capital (United States)

To access the full report, please click here.